THOUSAND OAKS, Calif.,
July 30, 2020 /PRNewswire/ -- Amgen
Inc. (NASDAQ: AMGN) announced today the commencement of nine
separate private offers to exchange (each, an "Exchange Offer" and,
collectively, the "Exchange Offers") certain specified series of
its outstanding senior notes (collectively, the "Old Notes") for a
combination of a cash payment and new Senior Notes due 2053 (the
"New Notes").
The Exchange Offers consist of the following:
(a) an offer to exchange the
6.90% Senior Notes due 2038;
(b) an offer to exchange the
6.375% Senior Notes due 2037;
(c) an offer to exchange the
6.40% Senior Notes due 2039;
(d) an offer to exchange the
5.75% Senior Notes due 2040;
(e) an offer to exchange the
5.65% Senior Notes due 2042;
(f) an offer to exchange the
5.375% Senior Notes due 2043;
(g) an offer to exchange the
5.15% Senior Notes due 2041;
(h) an offer to exchange the
4.95% Senior Notes due 2041; and
(i) an offer to exchange the
4.40% Senior Notes due 2045;
in each case, for New Notes, provided that the aggregate
principal amount of New Notes to be issued in the Exchange Offers
shall not exceed $800,000,000 (such
amount, the "Maximum Notes Exchange Cap"). In addition, the
aggregate amount of the New Notes Premium (as defined herein)
resulting from the Exchange Offers shall not exceed $350,000,000 (such amount, the "Maximum New Notes
Premium Cap").
The following table sets forth the series of Old Notes included
in the Exchange Offers:
CUSIP/ISIN
Number
|
Old
Notes
|
Principal
Amount
Outstanding
|
Reference U.S.
Treasury
Security
|
Bloomberg
Reference
Page
|
Fixed Spread
(basis points)
|
Acceptance
Priority
Level
|
Cash
Payment
Percent of
Premium(1)
|
031162AY6/US03
1162AY66
|
6.90% Senior
Notes due 2038
|
$290,616,000
|
2.000% UST
due February
15, 2050
|
FIT1
|
+100
|
1
|
40%
|
031162AW0/US03
1162AW01
|
6.375% Senior
Notes due 2037
|
$552,410,000
|
2.000% UST
due February
15, 2050
|
FIT1
|
+95
|
2
|
44%
|
031162BA7/US031
162BA71
|
6.40% Senior
Notes due 2039
|
$466,320,000
|
2.000% UST
due February
15, 2050
|
FIT1
|
+100
|
3
|
36%
|
031162BC3/
US031162BC38
|
5.75% Senior
Notes due 2040
|
$
412,120,000
|
2.000% UST
due February
15, 2050
|
FIT1
|
+105
|
4
|
27%
|
031162BH2/
US031162BH25
|
5.65% Senior
Notes due 2042
|
$487,020,000
|
2.000% UST
due February
15, 2050
|
FIT1
|
+110
|
5
|
20%
|
031162BP4/
US031162BP41
|
5.375% Senior
Notes due 2043
|
$261,077,000
|
2.000% UST
due February
15, 2050
|
FIT1
|
+110
|
6
|
10%
|
031162BK5/
US031162BK53
|
5.15% Senior
Notes due 2041
|
$974,045,000
|
2.000% UST
due February
15, 2050
|
FIT1
|
+105
|
7
|
11%
|
031162BE9/
US031162BE93
|
4.950% Senior
Notes due 2041
|
$600,000,000
|
2.000% UST
due February
15, 2050
|
FIT1
|
+110
|
8
|
6%
|
031162BZ2/US031
162BZ23
|
4.400% Senior
Notes due 2045
|
$2,250,000,000
|
2.000% UST
due February
15, 2050
|
FIT1
|
+125
|
9
|
0%
|
1.
|
The "Cash Payment
Percent of Premium" is the percent (as set forth with respect to
each series of Old Notes in the table above) of the amount by which
the Total Exchange Price (as defined herein and calculated at the
Price Determination Date (as defined herein)) exceeds $1,000 per
$1,000 principal amount of such series of Old Notes.
|
Subject to the terms and conditions of the Exchange Offers,
Amgen will accept for exchange the Old Notes of any series validly
tendered, and not validly withdrawn, in the Exchange Offers in
accordance with the applicable "Acceptance Priority Level" (in
numerical priority order) for such series as set forth in the table
above (each, an "Acceptance Priority Level"), with Acceptance
Priority Level 1 being the highest priority level. Subject to the
Maximum Notes Exchange Cap and/or the Maximum New Notes Premium
Cap, each series of Old Notes validly tendered in the Exchange
Offers that has a higher Acceptance Priority Level will be accepted
for exchange before any series of Old Notes validly tendered in the
Exchange Offers that has a lower Acceptance Priority Level. If the
remaining available portion of the Maximum Notes Exchange Cap or
the Maximum New Notes Premium Cap, as applicable, is not adequate
to permit the acceptance for exchange of all of the validly
tendered Old Notes of a series having a particular Acceptance
Priority Level, Amgen will allocate such available Maximum Notes
Exchange Cap or Maximum New Notes Premium Cap, as applicable, among
the aggregate principal amount of the validly tendered Old Notes of
such series on a pro rata basis, and any series of validly tendered
Old Notes having a lower Acceptance Priority Level will not be
accepted for exchange. As set forth in the Confidential Offering
Circular (as defined herein), Amgen may elect, in its sole
discretion, to increase the Maximum Notes Exchange Cap and/or the
Maximum New Notes Premium Cap, but is under no obligation to do
so.
All Old Notes that are tendered for exchange in the Exchange
Offers on or before the Early Participation Date (as defined
herein) will have priority over Old Notes that are tendered for
exchange after the Early Participation Date. If the principal
amount of Old Notes validly tendered and not validly withdrawn on
or before the Early Participation Date constitutes a principal
amount of Old Notes that, if accepted by Amgen, would result in
Amgen issuing New Notes having an aggregate principal amount equal
to or in excess of the Maximum Notes Exchange Cap, unless Amgen
elects, in its sole discretion, to increase the Maximum Notes
Exchange Cap, Amgen will not accept any Old Notes tendered for
exchange after the Early Participation Date (even if they are of
Acceptance Priority Level 1). In addition, if the aggregate
amount of the New Notes Premium resulting from Old Notes tendered
for exchange in the Exchange Offers on or before the Early
Participation Date, and accepted by Amgen, equals or exceeds the
Maximum New Notes Premium Cap, unless Amgen elects, in its sole
discretion, to increase the Maximum New Notes Premium Cap, Amgen
will not accept any Old Notes tendered for exchange after the Early
Participation Date (even if they are of Acceptance Priority Level
1).
The Exchange Offers will expire at 12:00 Midnight, New York City time, at the end of August 26, 2020 unless extended by Amgen (such
date and time, as it may be extended, the "Expiration Date"). The
Total Exchange Prices and the Exchange Prices (as defined herein)
for the Old Notes and the New Notes Coupon (as defined here) will
be determined at 10:00 a.m.,
New York City time, on
August 13, 2020, unless extended by
Amgen (such date and time, as it may be extended, the "Price
Determination Date").
Exchange Eligible Holders (as defined herein) that validly
tender and do not validly withdraw their Old Notes at or prior to
5:00 p.m., New York City time, on August 12, 2020, unless extended by Amgen (the
"Early Participation Date") will be eligible to receive the
applicable Total Exchange Price (as defined herein), which includes
an early exchange premium, which is equal to $30.00 in principal amount of New Notes for each
$1,000 principal amount of the
applicable series of Old Notes validly tendered and not validly
withdrawn at or prior to the Early Participation Date and accepted
for exchange (the "Early Exchange Premium"). Exchange Eligible
Holders of Old Notes who validly tender after the Early
Participation Date, but at or prior to the Expiration Date, will be
eligible to receive the applicable Exchange Price, but will not
receive the Early Exchange Premium.
Tenders of Old Notes in the Exchange Offers may be validly
withdrawn at any time at or prior to 5:00
p.m., New York City time,
on August 12, 2020 (the "Withdrawal
Date"), unless extended by Amgen, but not thereafter unless
additional withdrawal rights are required by law.
The Exchange Offers are being conducted by Amgen upon the terms
and subject to the conditions set forth in a confidential offering
circular, dated July 30, 2020 (the
"Confidential Offering Circular"). The Exchange Offers are only
intended for, and copies of the offering documents will only be
made available to, holders of outstanding Old Notes that have
certified their status as (1) a "Qualified Institutional Buyer" as
defined in Rule 144A under the Securities Act of 1933, as amended
(the "Securities Act"), in a private transaction in reliance upon
the exemption from the registration requirements of the Securities
Act provided by Section 4(a)(2) thereof, or (2) (A) a person other
than a "U.S. person" (as defined in Rule 902 of Regulation S under
the Securities Act), outside the United
States not purchasing for the account or benefit of a U.S.
person, (B) acquiring the New Notes in an offshore transaction in
accordance with Regulation S under the Securities Act and (C)
otherwise a Non-U.S. Qualified Offeree (as described in the
Confidential Offering Circular) (each such holder, an "Exchange
Eligible Holder" and, collectively, the "Exchange Eligible
Holders").
Upon the terms and subject to the conditions set forth in the
Confidential Offering Circular, Exchange Eligible Holders who
validly tender and who do not validly withdraw Old Notes at or
prior to the Early Participation Date, and whose Old Notes are
accepted for exchange by us, will receive the applicable Total
Exchange Price for each $1,000
principal amount of Old Notes in the form of a combination of a
principal amount of New Notes and cash with an aggregate value
equal to the Total Exchange Price, which includes the applicable
Early Exchange Premium, as follows:
(i) an aggregate principal
amount of New Notes equal to (x) the Total Exchange Price
applicable to such series of Old Notes minus (y) the Cash
Component (as defined herein); and
(ii) a cash payment equal to the
Cash Component.
The "Total Exchange Price" for each $1,000 principal amount of each series of Old
Notes validly tendered at or prior to the Early Participation Date,
and not validly withdrawn at or prior to the Withdrawal Date (each,
a "Total Exchange Price") will be calculated on the Price
Determination Date. The Total Exchange Price will be equal to the
discounted value (calculated in accordance with the formula set
forth in the Confidential Offering Circular) on the applicable
Settlement Date (as defined herein) of the remaining payments of
principal and interest through the earlier of the applicable
maturity date or par call date of such series of Old Notes (rounded
to the nearest cent per $1,000
principal amount of such Old Notes), using a yield (the "Exchange
Offer Yield") equal to the sum of:
(i) the bid-side yield on the
applicable U.S. Treasury Security set forth in the corresponding
tables above as displayed on the applicable Bloomberg reference
page (or any recognized quotation source selected by the dealer
managers in their sole discretion if such quotation report is not
available or is manifestly erroneous), plus
(ii) the applicable fixed spread
set forth in the corresponding tables above;
less accrued and unpaid interest to, but not including,
the applicable Settlement Date.
Each Total Exchange Price is inclusive of the applicable Early
Exchange Premium. The price for each $1,000 principal amount of each series of Old
Notes validly tendered after the Early Participation Date, but at
or prior to the Expiration Date (each, an "Exchange Price") is
equal to:
(i) an aggregate principal amount
of New Notes equal to (x) the Total Exchange Price applicable to
such series of Old Notes minus (y) the Cash Component
minus (z) the Early Exchange Premium; and
(ii) a cash payment equal to the
Cash Component.
The "Cash Component" means the portion of the Total Exchange
Price to be paid to Exchange Eligible Holders in cash and is equal
to (x) the applicable Cash Payment Percent of Premium for such
series of Old Notes multiplied by (y) (i) the applicable
Total Exchange Price for such series of Old Notes minus (ii)
$1,000.
The "Cash Payment Percent of Premium" is the percent (as set
forth with respect to each series of Old Notes in the table above)
of the amount by which the Total Exchange Price (as calculated at
the Price Determination Date) exceeds $1,000 per $1,000
principal amount of such Old Notes. For the avoidance of doubt, the
Cash Component payable with respect to each series of Old Notes
validly tendered at or prior to the Early Participation Date, and
accepted by Amgen for exchange, will be equivalent to the Cash
Component payable with respect to such series of Old Notes validly
tendered after the Early Participation Date and at or prior to the
Expiration Date, and accepted by Amgen for exchange.
The Total Exchange Price and Exchange Price for the applicable
series of Old Notes may be adjusted as described herein.
Amgen will announce the Exchange Offer Yield, Total Exchange
Price, Exchange Price and Cash Component for each of the Old Notes
promptly after they are determined by the dealer managers. Exchange
Eligible Holders who receive New Notes in exchange for Old Notes on
the Final Settlement Date (as defined herein) will receive New
Notes that will, if the Early Settlement Date (as defined herein)
has occurred, have an embedded entitlement to pre-issuance interest
for the period from, and including, the Early Settlement Date to,
but not including, the Final Settlement Date. As a result, the cash
payable for accrued and unpaid interest on the Old Notes exchanged
on the Final Settlement Date will be reduced by the amount of
pre-issuance interest on the New Notes exchanged therefor.
The Total Exchange Price payable by Amgen for each $1,000 principal amount of Old Notes tendered for
exchange, and accepted by Amgen, will consist of a combination of
cash and a principal amount of New Notes (together, a "Payment
Amount") equal to the applicable Total Exchange Price of the series
of Old Notes tendered.
The Exchange Prices will be paid in the same manner as the Total
Exchange Prices except that the principal amount of New Notes
constituting a portion of the Payment Amount will be reduced by the
Early Exchange Premium.
Amgen may, at its option, elect to increase or decrease the
principal amount of New Notes exchangeable for each $1,000 principal amount of the applicable Old
Notes tendered and accepted by up to $100 per $1,000
principal amount. Such adjustments would affect the composition,
but not the amount, of the Total Exchange Price and the Exchange
Price for such series of Old Notes. Amgen expects any such election
to be made as of the Price Determination Date, which is expected to
be August 13, 2020.
In addition to the applicable Total Exchange Price or applicable
Exchange Price, Exchange Eligible Holders whose Old Notes are
accepted for exchange will be paid accrued and unpaid interest on
such Old Notes to, but not including, the applicable Settlement
Date in cash.
The New Notes will bear interest at a rate per annum (the "New
Notes Coupon") equal to the sum of (i) the bid-side yield on the
2.000% U.S. Treasury Bond due February 15,
2050, as calculated on the Price Determination Date and (ii)
1.4% (140 basis points).
The "New Notes Premium" with respect to $1,000 principal of each series of Old Notes
tendered in the Exchange Offers is an amount equal to the sum of
the issue price of New Notes issued in exchange for such series of
Old Notes for U.S. federal income tax purposes (which is generally
equal to the fair market value of the New Notes as of their date of
first issuance and, solely for purposes of this definition, shall
be assumed to be par) multiplied by the exchange ratio
(taking into account the difference between the early and late
settlement exchange ratios, as may be appropriate, as estimated by
Amgen in its sole discretion), plus the Cash Component
payable for such series of Old Notes, minus $1,000.
Each Exchange Offer is subject to certain conditions, including,
but not limited to, the following: (i) the condition that the
combination of the yield of the New Notes and the Total Exchange
Price for the applicable series of Old Notes would result in the
New Notes and such Old Notes not being treated as "substantially
different" under ASC 470-50 (the "Accounting Treatment Condition"),
(ii) the condition that a minimum of $300
million aggregate principal amount of New Notes be issued in
exchange for outstanding Old Notes validly tendered and not validly
withdrawn (the "Minimum Issue Condition"), (iii) the Yield
Condition (as defined herein) and (iv) that there shall not have
been any change or development that in Amgen's reasonable judgment
materially reduces the anticipated benefits to it of the applicable
Exchange Offer or that has had, or could reasonably be expected to
have, a material adverse effect on it, its businesses, condition
(financial or otherwise) or prospects. Notwithstanding any other
provision of the Exchange Offers, if on the Price Determination
Date the bid-side yield on the 2.000% U.S. Treasury Bond due
February 15, 2050 (as used to
determine the interest rates for the New Notes) is less than or
more than the applicable percentages for such series of Old Notes
set forth in Annex B to the Confidential Offering Circular, Amgen
will not be required to accept for exchange, or to issue New Notes
in exchange for the Old Notes of such series and may terminate or
amend the Exchange Offer with respect to such series (the "Yield
Condition"). The Exchange Offers are subject to (i) an aggregate
issuance limit with respect to the aggregate principal amount of
New Notes equal to the Maximum Notes Exchange Cap and (ii) a limit
on the aggregate amount of the New Notes Premium resulting from the
Exchange Offers equal to the Maximum New Notes Premium Cap, as
discussed above. The calculation of the New Notes Premium resulting
from the Exchange Offers will be made in Amgen's sole
discretion.
Amgen reserves the right, but is under no obligation, at any
point following the Early Participation Date and before the
Expiration Date, to accept for exchange any Old Notes validly
tendered at or prior to the Early Participation Date (the date of
such exchange, the "Early Settlement Date"). The Early Settlement
Date will be determined at Amgen's option and is currently expected
to occur on August 17, 2020, the
third business day immediately following the Early Participation
Date. If, after the Early Participation Date, Amgen chooses to
exercise its option to have an Early Settlement Date and all
conditions to the relevant Exchange Offers have been or are
concurrently satisfied or waived by Amgen, including satisfaction
or waiver of the Accounting Treatment Condition, the Minimum Issue
Condition and the Yield Condition, and subject to each of the
Maximum Notes Exchange Cap and the Maximum New Notes Premium Cap,
Amgen will accept for exchange all Old Notes validly tendered in
the Exchange Offers prior to the Early Participation Date, and the
exchange for such Old Notes will be made on the Early Settlement
Date.
The "Final Settlement Date" for the Exchange Offers will be
promptly after the Expiration Date and is currently expected to
occur on August 28, 2020, the second
business day immediately following the Expiration Date. Each of the
Early Settlement Date and the Final Settlement Date is referred to
as a "Settlement Date."
The complete terms of the Exchange Offers are described in the
Confidential Offering Circular. Amgen reserves the right, subject
to applicable law, to extend, terminate or otherwise amend the
terms of any or all of the Exchange Offers.
If and when issued, the New Notes will not be registered under
the Securities Act or any state securities laws. Therefore, the New
Notes may not be offered or sold in the
United States absent registration or an applicable exemption
from the registration requirements of the Securities Act and any
applicable state securities laws. Amgen will enter into a
registration rights agreement with respect to the New Notes
providing for certain registration rights with respect to the New
Notes as described in the Confidential Offering Circular.
Documents relating to the Exchange Offers will be distributed
only to holders of the outstanding Old Notes that complete and
return the letter of eligibility confirming that they are Exchange
Eligible Holders. Holders of the outstanding Old Notes that desire
to review the eligibility letter may visit the website for this
purpose at http://www.dfking.com/amgn or contact
D.F. King & Co., Inc., the information agent for the Exchange
Offers, by calling toll-free (800) 814-8954 or at (212) 269-5550
(banks and brokerage firms) or email amgen@dfking.com.
This press release is not an offer to sell or a solicitation
of an offer to buy any security. The Exchange Offers are being made
solely by the Confidential Offering Circular and only to such
persons and in such jurisdictions as is permitted under applicable
law.
In particular, this communication is only addressed to and
directed at: (A) in any Member State of the European Economic Area
or the United Kingdom that has
implemented the Prospectus Directive, qualified investors in that
Member State within the meaning of the Prospectus Directive and (B)
(i) persons that are outside the United
Kingdom or (ii) persons in the United Kingdom who are investment
professionals falling within Article 19(5) of the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005 (the
"Order") or fall within Article 43 of the Order, or any other
person to whom it may otherwise lawfully be communicated under the
Order (all such persons together being referred to as "relevant
persons"). The New Notes are only available to, and any invitation,
offer or agreement to subscribe, purchase or otherwise acquire such
New Notes will be engaged in only with, relevant persons. Any
person who is not a relevant person should not act or rely on this
document or any of its contents.
About Amgen
Amgen is committed to unlocking the potential of biology for
patients suffering from serious illnesses by discovering,
developing, manufacturing and delivering innovative human
therapeutics. This approach begins by using tools like advanced
human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer
since 1980, Amgen has grown to be one of the world's leading
independent biotechnology companies, has reached millions of
patients around the world and is developing a pipeline of medicines
with breakaway potential.
Forward-Looking Statements
This news release contains forward-looking statements that are
based on the current expectations and beliefs of Amgen. All
statements, other than statements of historical fact, are
statements that could be deemed forward-looking statements,
including any statements on the outcome, benefits and synergies of
collaborations, or potential collaborations, with any other
company, including Adaptive Biotechnologies (including statements
regarding such collaboration's, or our own, ability to discover and
develop fully-human neutralizing antibodies targeting SARS-CoV-2 to
potentially prevent or treat COVID-19), BeiGene, Ltd., or the
Otezla® (apremilast) acquisition, including anticipated Otezla
sales growth and the timing of non-GAAP EPS accretion, as well as
estimates of revenues, operating margins, capital expenditures,
cash, other financial metrics, expected legal, arbitration,
political, regulatory or clinical results or practices, customer
and prescriber patterns or practices, reimbursement activities and
outcomes, effects of pandemics or other widespread health problems
such as the ongoing COVID-19 pandemic on our business, outcomes,
progress or effects relating to studies of Otezla as a potential
treatment for COVID-19, the timing and completion of the Exchange
Offers and other such estimates and results. Forward-looking
statements involve significant risks and uncertainties, including
those discussed below and more fully described in the Securities
and Exchange Commission reports filed by Amgen, including our most
recent annual report on Form 10-K and any subsequent periodic
reports on Form 10-Q and current reports on Form 8-K. Unless
otherwise noted, Amgen is providing this information as of the date
of this news release and does not undertake any obligation to
update any forward-looking statements contained in this document as
a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual
results may differ materially from those we project. Our results
may be affected by our ability to successfully market both new and
existing products domestically and internationally, clinical and
regulatory developments involving current and future products,
sales growth of recently launched products, competition from other
products including biosimilars, difficulties or delays in
manufacturing our products and global economic conditions. In
addition, sales of our products are affected by pricing pressure,
political and public scrutiny and reimbursement policies imposed by
third-party payers, including governments, private insurance plans
and managed care providers and may be affected by regulatory,
clinical and guideline developments and domestic and international
trends toward managed care and healthcare cost containment.
Furthermore, our research, testing, pricing, marketing and other
operations are subject to extensive regulation by domestic and
foreign government regulatory authorities. We or others could
identify safety, side effects or manufacturing problems with our
products, including our devices, after they are on the market. Our
business may be impacted by government investigations, litigation
and product liability claims. In addition, our business may be
impacted by the adoption of new tax legislation or exposure to
additional tax liabilities. If we fail to meet the compliance
obligations in the corporate integrity agreement between us and the
U.S. government, we could become subject to significant sanctions.
Further, while we routinely obtain patents for our products and
technology, the protection offered by our patents and patent
applications may be challenged, invalidated or circumvented by our
competitors, or we may fail to prevail in present and future
intellectual property litigation. We perform a substantial amount
of our commercial manufacturing activities at a few key facilities,
including in Puerto Rico, and also
depend on third parties for a portion of our manufacturing
activities, and limits on supply may constrain sales of certain of
our current products and product candidate development. An outbreak
of disease or similar public health threat, such as COVID-19, and
the public and governmental effort to mitigate against the spread
of such disease, could have a significant adverse effect on the
supply of materials for our manufacturing activities, the
distribution of our products, the commercialization of our product
candidates, and our clinical trial operations, and any such events
may have a material adverse effect on our product sales, product
development, business and results of operations. We rely on
collaborations with third parties for the development of some of
our product candidates and for the commercialization and sales of
some of our commercial products. In addition, we compete with other
companies with respect to many of our marketed products as well as
for the discovery and development of new products. Discovery or
identification of new product candidates or development of new
indications for existing products cannot be guaranteed and movement
from concept to product is uncertain; consequently, there can be no
guarantee that any particular product candidate or development of a
new indication for an existing product will be successful and
become a commercial product. Further, some raw materials, medical
devices and component parts for our products are supplied by sole
third-party suppliers. Certain of our distributors, customers and
payers have substantial purchasing leverage in their dealings with
us. The discovery of significant problems with a product similar to
one of our products that implicate an entire class of products
could have a material adverse effect on sales of the affected
products and on our business and results of operations. Our efforts
to collaborate with or acquire other companies, products or
technology, and to integrate the operations of companies or to
support the products or technology we have acquired, may not be
successful. A breakdown, cyberattack or information security breach
could compromise the confidentiality, integrity and availability of
our systems and data. Our stock price is volatile and may be
affected by a number of events. Our business performance could
affect or limit the ability of our Board of Directors to declare a
dividend or our ability to pay a dividend or repurchase our common
stock. We may not be able to access the capital and credit markets
on terms that are favorable to us, or at all.
CONTACT: Amgen, Thousand
Oaks
Trish Rowland, 805-447-5631
(media)
Megan Fox, 805-447-1423 (media)
Arvind Sood, 805-447-1060
(investors)
View original content to download
multimedia:http://www.prnewswire.com/news-releases/amgen-commences-exchange-offers-for-certain-series-of-outstanding-senior-notes-from-exchange-eligible-holders-301103054.html
SOURCE Amgen